13 studies were found.

1.		No longer recruiting	6-Hydroxymethylacylfulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer Conditions: recurrent pancreatic cancer; stage III pancreatic cancer; stage IV pancreatic cancer; adenocarcinoma of the pancreas
2.		Completed	BMS-184476 in Treating Patients With Advanced Solid Tumors Condition: unspecified adult solid tumor, protocol specific
3.		No longer recruiting	CCI-779 in Treating Patients With Advanced Solid Tumors Conditions: recurrent adult brain tumor; unspecified adult solid tumor, protocol specific; brain metastases
4.		No longer recruiting	Chemotherapy in Treating Patients With Advanced Solid Tumors Condition: unspecified adult solid tumor, protocol specific
5.		No longer recruiting	Chemotherapy in Treating Patients With Advanced Solid Tumors Condition: unspecified adult solid tumor, protocol specific
6.		No longer recruiting	Chemotherapy in Treating Patients With Advanced Solid Tumors Condition: unspecified adult solid tumor, protocol specific
7.		Recruiting	Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer Conditions: Colon Cancer; Rectal Cancer
8.		No longer recruiting	Combination Chemotherapy in Treating Patients With Advanced Cancer Condition: unspecified adult solid tumor, protocol specific
9.		Completed	Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors Condition: Cancer
10.		Completed	G3139 and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer Conditions: recurrent colon cancer; adenocarcinoma of the rectum; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer; ...
11.		No longer recruiting	Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors Condition: unspecified adult solid tumor, protocol specific
12.		No longer recruiting	LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function Condition: unspecified adult solid tumor, protocol specific
13.		No longer recruiting	Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer Conditions: stage IV breast cancer; recurrent breast cancer; Male Breast Cancer